ReviewClinical cancer research : an official journal of the American Association for Cancer Research2007
Toll-like receptors in tumor immunotherapy.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- Common variants in toll-like receptor family genes and risk of gastric cancer: a systematic review and meta-analysis.Frontiers in genetics · 2023Pooled it
- Molecular prognostic indicators in HPV-positive oropharyngeal cancer: an updated review.Clinical & experimental metastasis · 2022Pooled it
- T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Trial
- Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Article
- Rapid and label-free isolation of human peripheral blood monocytes using a reversible CD36-binding aptamer for cell capture.Biomaterials science · 2025Article
- Quantification of the Actin-Binding Protein Flightless-I in Human Serum by Automated Western Blot System and Investigation of Its Diagnostic Potential in Sepsis.Biomedicines · 2025Article
- Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.Journal for immunotherapy of cancer · 2024Article
- Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches.Medical oncology (Northwood, London, England) · 2024Review
- Gastric Cancer, Immunotherapy, and Nutrition: The Role of Microbiota.Pathogens (Basel, Switzerland) · 2024Review
- Role of toll-like receptor in the pathogenesis of oral cancer.Cell biochemistry and biophysics · 2024Review
- Advanced T and Natural Killer Cell Therapy for Glioblastoma.Journal of Korean Neurosurgical Society · 2023Article
- Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives.Biomarker research · 2022Review
- Understanding the role of Toll-like receptors in lung cancer immunity and immunotherapy.Frontiers in immunology · 2022Review
- Pigmentation Levels Affect Melanoma Responses toInternational journal of molecular sciences · 2021Article
- Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects.Cancers · 2020Review
- Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions.Biomarker research · 2020Review
- Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103Journal of extracellular vesicles · 2019Article
- MiR-6991-3p is identified as a novel suppressor in the expansion and activation of myeloid-derived suppressor cells in hepatoma-bearing mice.OncoTargets and therapy · 2019Article
- Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges.Biomedicines · 2018Review
- Methods for improving the immunogenicity and efficacy of cancer vaccines.Expert opinion on biological therapy · 2018Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
Lymphodepletion with chemotherapeutic agents or total body irradiation (TBI) before adoptive transfer of tumor-specific T cells is a critical advancement in the treatment of patients with melanoma. More than 50% of patients that are refractory to other treatments experience an objective or curative response with this approach. Emerging data indicate that the key mechanisms underlying how TBI augments the functions of adoptively transferred T cells include (a) the depletion of regulatory T cells (T(reg)) and myeloid-derived suppressor cells that limit the function and proliferation of adoptively transferred cells; (b) the removal of immune cells that act as "sinks" for homeostatic cytokines, whose levels increase after lymphodepletion; and (c) the activation of the innate immune system via Toll-like receptor 4 signaling, which is engaged by microbial lipopolysaccharide that translocated across the radiation-injured gut. Here, we review these mechanisms and focus on the effect of Toll-like receptor agonists in adoptive immunotherapy. We also discuss alternate regimens to chemotherapy or TBI, which might be used to safely treat patients with advanced disease and promote tumor regression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.